UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data

Group 1 - Ascendis Pharma A/S (NASDAQ:ASND) is recognized as one of the top biotech stocks to invest in, with UBS reaffirming a price target of $307 and a Buy rating on September 23 due to MBX's clinical study for treating persistent hypoparathyroidism [1][2] - Yorvipath shows higher placebo-adjusted response rates of 52.9% at 4 weeks and 69% at 26 weeks in clinical trials, indicating that Ascendis Pharma's medication remains a leader in the hypoparathyroidism treatment market despite competition [2] - UBS estimates the hypoparathyroidism market to be over $10 billion, suggesting significant sales potential for Yorvipath in the short and medium term, while the MBX data release alleviates concerns for Ascendis Pharma [2][3] Group 2 - Ascendis Pharma A/S is a biopharmaceutical company focused on developing and distributing innovative treatments for unmet medical needs, particularly in oncology and endocrinology [3]